Bayer enters into collaboration with Seattle Genetics for development of anticancer drugs
06:07 AM | June 26, 2013 | Deepti Ramesh
Bayer says that its Bayer HealthCare subgroup has entered into a new antibody-drug conjugate (ADC) collaboration with biotechnology company Seattle Genetics (Bothell, WA). Bayer, under the deal, will...
This information is only available to subscribers.
chemweek.com is the one stop platform for chemical news, data and analysis across all industry sectors and geographies.